Daisuke Yoshimoto

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response.

DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response.

Journal: Cancer science

Published: June 25, 2025

Downregulation of HLA Class I Expression through HLA-A DNA Methylation Is Associated with Reduced CD8+ T-cell Infiltration in Cervical Cancer.

Downregulation of HLA Class I Expression through HLA-A DNA Methylation Is Associated with Reduced CD8+ T-cell Infiltration in Cervical Cancer.

Journal: Cancer immunology research

Published: May 09, 2025

Elucidating Alterations in Viral and Human Gene Expression Due to Human Papillomavirus Integration by Using Multimodal RNA Sequencing.

Elucidating Alterations in Viral and Human Gene Expression Due to Human Papillomavirus Integration by Using Multimodal RNA Sequencing.

Journal: Viruses

Published: May 01, 2025

BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis.

BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis.

Journal: Cancer science

Published: February 03, 2025

Impact of human papillomavirus types on uterine cervical neoplasia.

Impact of human papillomavirus types on uterine cervical neoplasia.

Journal: The journal of obstetrics and gynaecology research

Published: May 11, 2024

Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia.

Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia.

Journal: HLA

Published: January 29, 2024

Identification of target cells of human papillomavirus 18 using squamocolumnar junction organoids.

Identification of target cells of human papillomavirus 18 using squamocolumnar junction organoids.

Journal: Cancer science

Published: May 29, 2023

Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial.

Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial.

Journal: The journal of obstetrics and gynaecology research

Published: December 30, 2021

Showing 1-8 of 8

Last Updated: 09/26/2026